Valuation: 4basebio PLC

Market Cap 81.58M 110M 95.23M 88.93M 153M 10.48B 156M 1.04B 410M 5.25B 413M 404M 17.36B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 81.88M 110M 95.58M 89.25M 154M 10.52B 156M 1.05B 411M 5.27B 415M 406M 17.42B EV / Sales 2026 *
29.2x
EV / Sales 2027 * 8.94x
Free-Float
38.75%
Yield 2026 *
-
Yield 2027 * -
3 months+15.38%
6 months-6.25%
Current year-14.63%
1 week 502.5
Extreme 502.5
550
1 month 500
Extreme 500
550
Current year 420
Extreme 420
630
1 year 420
Extreme 420
1,000
3 years 420
Extreme 420
1,820
5 years 390
Extreme 390
1,820
10 years 175
Extreme 175
1,820
Manager TitleAgeSince
Chief Executive Officer 33 10/02/2026
Chief Tech/Sci/R&D Officer - 01/03/2025
Chief Operating Officer - 12/03/2026
Director TitleAgeSince
Director/Board Member 48 22/12/2020
Director/Board Member 33 08/08/2024
Chairman 60 08/07/2025
Date Insider Type Main position Quantity % Market Cap.
16/02/26 Buy

Chief Executive Officer

2,650 0.0171%
11/02/26 Buy

Director

3,000 0.0193%
11/02/26 Buy

Director

1,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-45.88%-11.76% 110M
+0.99%+1.78%+5.07%+16.49% 49.47B
+3.71%+9.40%+486.14%+579.98% 43.97B
+5.60%+10.21%+20.85%+81.78% 39.6B
+2.70%+1.57%+32.71%+9.07% 39.29B
+2.21%+6.75%+20.20%+54.40% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+35.99%+124.45% 16.49B
-0.11%+2.41%+5.03%+20.47% 14.01B
+0.75%+15.04%+79.84%+29.70% 12.77B
Average +1.90%+5.69%+71.11%+100.51% 26.5B
Weighted average by Cap. +2.54%+6.10%+105.07%+138.61%

Financials

2026 *2027 *
Net sales 2.8M 3.78M 3.27M 3.05M 5.27M 360M 5.35M 35.81M 14.06M 180M 14.19M 13.88M 596M 12M 16.19M 14.01M 13.08M 22.57M 1.54B 22.93M 153M 60.24M 772M 60.81M 59.48M 2.55B
Net income -17.1M -23.08M -19.96M -18.64M -32.16M -2.2B -32.67M -219M -85.84M -1.1B -86.66M -84.76M -3.64B -
Net Debt 300K 405K 350K 327K 564K 38.53M 573K 3.84M 1.51M 19.31M 1.52M 1.49M 63.85M 25.7M 34.68M 30M 28.02M 48.34M 3.3B 49.11M 329M 129M 1.65B 130M 127M 5.47B
Logo 4basebio PLC
4basebio PLC is a United Kingdom-based life biotechnology company. The Company is focused on the development of advanced therapy medicinal products (ATMPs) through its synthetic Deoxyribonucleic acid (DNA) products and non-viral, cell-targeting nucleic acid delivery platform. The Company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. Its synthetic DNA is produced via an enzymatic, cell-free manufacturing process. It utilizes a technology for primer-free DNA amplification called TruePrime, which enables high-yield and quality DNA production. By combining two enzymes, Trueprime technology achieves isothermal multiple displacement DNA amplification in a continuous cell-free process with high fidelity. The Company offers application-specific synthetic DNA solutions across mRNA vaccines and therapies, viral vectors, gene editing, DNA vaccines and non-viral delivery.
Employees
140
Date Price Change Volume
07/08/26 GBX 525.00 0.00% 43
06/08/26 GBX 525.00 0.00% 584
05/08/26 GBX 525.00 0.00% 72
04/08/26 GBX 525.00 0.00% 500
03/08/26 GBX 525.00 0.00% 28
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.250GBP
Average target price
16.00GBP
Spread / Average Target
+204.76%

Annual profits - Rate of surprise